Biting the data bullet at GlaxoSmithKline

May 15, 2019 Jane 0

GSK’s size undoubtedly makes it a big ship to turn when integrating new tools like machine learning. What this case study shows is that the focus of any organisation today – both large and small, must be on positioning their infrastructure and their personnel in such a way that new trends can be utilised quickly to retain competitive advantage.

Here the author of The AI Advantage, Thomas H. Davenport, examines how GlaxoSmithKline R&D successfully transformed their data allowing them to utilise AI and lay the foundation for creating better drugs, quicker.

Many large organizations eventually realize that they don’t have the data environments they need to succeed with broad-scale AI to work. For GlaxoSmithKline’s (GSK) Research and Development (R&D) organization, that time was in early 2015. The president (at that time) of the unit Patrick Vallance and his senior colleagues deliberated on whether their data environment was of sufficient quality and integration to use tools like machine learning to help develop new drugs…

Attached Issue № 0219

Collaboration, Translation And The Future Of Microbiome Innovation

April 17, 2019 root 0

Translation. When we hear this word, it may evoke feelings of excitement, adventure and possibility that come with learning different languages or travelling to a foreign country. For scientists, ‘translation’ also suggests moving research findings from the laboratory into clinical practice. Just as words are translated, so too are research findings.

Read more…

Attached Issue № 0219
Biostart-Magazine-Sitting-Down-With

David Kyle, Evolve Biosystems

March 27, 2019 Jane 0

Dr. David Kyle has co-founded biotech companies for 35 years in nutrition and health including Martek Biosciences which was acquired in 2011 for $1.1 billion. For the first issue of Biostart, he spoke to us about the lessons he’s learned during his career.

Where did Evolve begin?

Evolve’s work is based on 15 years of previous research at the University of California at Davis. A cross-functional team of world-class scientists made an incredible discovery. The early microbiome of the infant is defined by the 15% of energy in human breast milk that is not directly available to the infant, but rather it is tied up in a soluble fibre (Human Milk Oligosaccharides or HMO) that feeds the new-born infant gut microbiome.

Interestingly, only a single bacterial species, Bifidobacterial infantis, has the capability for completely consuming all those HMO and remarkably, this species has been lost from most infants in the developed world due primarily to a lifetime exposure to antibiotics. The seeding of an infant’s gut microbiome has historically come from its mother’s gut microbiome, but mothers in the U.S. today have had 15-20 courses of antibiotics from the time they were born until the time they deliver their first baby. Her microbiome diversity has been depleted significantly, including this important symbiont and if mom does not have the B. infantis, she cannot pass it on to her baby and the symbiosis has…

Attached Issue № 0219

Investing in the future

March 13, 2019 Jane 0

Charlie Curtis teaches businesses how to innovate, focusing on the positive impact they can have for future generations. But keen to have a positive impact himself, Charlie, alongside his business partner Tim Kruger, starts revolutionary new ventures to address environmental issues.

Everyone should have a wilderness experience where they walk across a desert or climb a mountain or cycle across a country. In 2008, I spent three months in a small boat with three others, sailing from Argentina to Cape Town via the Antarctic. The camaraderie with a team that size is…

Charting A Translational Roadmap In The Microbiome Space

February 6, 2019 root 0

The opportunity afforded by the microbiome for developing therapeutic and wellness products is matched only by the formidable task of unraveling the science of the microbiome in the first place. Microbiome research is transitioning from a descriptive to a more mechanistic science, and progress in understanding mechanisms that underpin microbiome biology is likely to result in a surge of interest in this space on the part of the biotech, pharma and investor communities.

Read more…